Lacidipina Mylan Pharma (Lacidipine)

Lacidipine is used to manage high blood pressure, a key component of cardiovascular disease management.

• Hypertension: Lowers systolic and diastolic blood pressure, helping to reduce the risk of cardiovascular events.

• Lacidipine selectively blocks L-type calcium channels in vascular smooth muscle, preventing calcium influx that is necessary for contraction. This inhibition leads to relaxation of arterial smooth muscle, vasodilation, and a consequent reduction in peripheral vascular resistance, thereby lowering blood pressure.

Lacidipine may cause several adverse reactions, ranging from mild to serious.

Common Side Effects

• Headache: mild to moderate intensity.
• Flushing: transient warmth and redness of the skin.
• Peripheral edema: swelling of the ankles or lower legs.
• Dizziness or light‑headedness, especially after standing.
• Tachycardia: increased heart rate.
• Nausea: occasional stomach upset.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure leading to fainting.
• Myocardial infarction: rare occurrence of heart attack.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Allergic reactions: rash, pruritus, or urticaria.
• Angioedema: swelling of face, lips, or throat.
• Cardiovascular collapse: extremely rare life‑threatening event.

When prescribing lacidipine, clinicians should consider several safety measures.

• Blood pressure monitoring: regularly assess to avoid excessive hypotension.
• Hepatic impairment: use with caution; adjust dose if liver function is compromised.
• Elderly patients: start at lower doses due to increased sensitivity.
• Concomitant antihypertensives: monitor for additive blood‑pressure lowering effects.
• Severe hypotension: contraindicated in patients with markedly low blood pressure.
• Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Lacidipine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase lacidipine plasma levels.
• Grapefruit juice: can markedly raise drug concentrations.
• Other potent antihypertensives: risk of additive hypotension.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness.
• Additional calcium‑channel blockers: monitor for cumulative effects.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive response.
• Diuretics: watch for electrolyte disturbances.
• Beta‑blockers: assess for excessive heart‑rate reduction.